Document Detail

Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in Spain: The ECOBIM Study.
MedLine Citation:
PMID:  23013427     Owner:  NLM     Status:  Publisher    
Background: Weight management is considered a key therapeutic strategy in type 2 diabetes mellitus. However, little is known about the impact of weight loss or body mass index (BMI) reduction on type 2 diabetes-related healthcare costs. Objective: The aim of this study was to estimate the economic impact of change in BMI among patients with type 2 diabetes mellitus from the Spanish healthcare system perspective. Methods: The ECOBIM study is an observational, non-interventional study in which data on BMI change and costs incurred by patients with type 2 diabetes were collected cross-sectionally and retrospectively for a 12-month period. Generalized linear mixed models were applied to estimate the effects of (i) BMI change in general (one-slope model); (ii) BMI gain and no BMI gain (two-slope model); and (iii) BMI gain and no BMI gain among obese and non-obese patients (four-slope model). Results: We studied 738 patients with a mean (SD) age of 66 (11) years and BMI of 30.6 (5.2) kg/m2. During the 12-month study period, 41.2% of patients gained BMI (BMI gainers) and 58.8% experienced either loss (52.2%) or no change (6.6%) in BMI (non-BMI gainers). One-unit gain (or loss) in BMI was significantly (p < 0.001) associated with a 2.4% cost increase (or decrease) [one-slope model]. Every unit gain in BMI was associated with a 20.0% increase in costs among BMI gainers while losing one unit was associated with an 8.0% decrease in costs among non-BMI gainers (two-slope model, p < 0.01). The economic benefit associated with reducing one BMI unit was 9.4% cost decrease in obese and 2.7% in non-obese patients (4-slope model). Conclusion: An increase in BMI among patients with type 2 diabetes was associated with increased 1-year direct healthcare costs. A reduction in BMI was associated with appreciable short-term economic benefits, especially in obese patients.
Tatiana Dilla; Amparo Valladares; Claudia Nicolay; Javier Salvador; Jesús Reviriego; María Costi
Related Documents :
17145567 - Self-reported dry eyes and diabetic history.
23813757 - The association of skin intrinsic fluorescence with type 1 diabetes complications in th...
24344937 - How severe is diabetes after total pancreatectomy? a case-matched analysis.
24756247 - Metabolic syndrome prevalence in psoriasis : a cross-sectional study in the italian pop...
22558567 - A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport i...
14654217 - Low-level ectopic expression of fushi tarazu in drosophila melanogaster results in ftz(...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-27
Journal Detail:
Title:  Applied health economics and health policy     Volume:  -     ISSN:  1179-1896     ISO Abbreviation:  Appl Health Econ Health Policy     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101150314     Medline TA:  Appl Health Econ Health Policy     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Medical Department, Lilly, Alcobendas, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thrombo...
Next Document:  Economic Implications of Rasburicase Treatment in Adult Patients with Tumour Lysis Syndrome.